Article

Baseline risk factors associated with immune related adverse events and atezolizumab

2022-11-18

Abstract excerpt

<h4>Background</h4> Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer patients in the last decade, but immune-related adverse events (irAEs) pose significant clinical challenges. Despite advances in the management of these unique toxicities, there remains an unmet need to further characterize the patient-level drivers of irAEs in order to optimize the benefit/risk balance in patients...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ebde1094-bcce-51d2-82c0-a76816fb695c
DOI: 10.1101/2022.11.16.22282410

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Baseline risk factors associated with immune related adverse events and atezolizumabDOI 10.1101/2022.11.16.22282410Read

Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity Read

Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.Semantic proximity Read

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in PolandSemantic proximity Read

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read

The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitorsSemantic proximity Read

Association of Blood Biomarkers and Autoimmunity with Immune Related Adverse Events in Patients with Cancer treated with Immune Checkpoint InhibitorsSemantic proximity Read

Immune-related adverse-event signals of durvalumab: cross-database pharmacovigilance analysis of WHO-VigiAccess and FAERS with comparative assessment versus atezolizumabSemantic proximity Read

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity Read

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver diseaseSemantic proximity Read

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.Semantic proximity Read